Cirio advises Elypta on its SEK 210 million financing round

Elypta AB, a Swedish cancer diagnostics company, has successfully raised SEK 210 million in a series A financing round. The investment was led by Bonnier Ventures and was joined by existing owners such as Wallenberg Investment’s venture capital arm Navigare Ventures, Industrifonden, Norrsken VC, Nina Capital, Chalmers Ventures and Hillclimber. The funding will be used to develop the company’s two leading studies – blood and urine tests for Multi-Cancer Early Detection (MCED) in adults with no symptoms of cancer and for detection of recurrence in kidney cancer patients.

Elypta is a Stockholm-based cancer diagnostics company based focused on reducing cancer mortality through earlier detection and closer monitoring. Elypta is advancing a broad multicentre study program on different cancers with the leading indications being early detection of recurrence in renal cell carcinoma and multi-cancer screening. www.elypta.com.

Cirio’s team consisted of Per Hedman, Jessica Grönberg and Luka Rosko.

For more information, please contact: